Moors & Cabot Inc. Decreases Stock Holdings in GSK plc (NYSE:GSK)

Moors & Cabot Inc. reduced its holdings in shares of GSK plc (NYSE:GSK) by 1.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,610 shares of the pharmaceutical company’s stock after selling 389 shares during the quarter. Moors & Cabot Inc.’s holdings in GSK were worth $900,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Indiana Trust & Investment Management Co lifted its position in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Crews Bank & Trust acquired a new position in shares of GSK during the fourth quarter worth $26,000. ST Germain D J Co. Inc. lifted its position in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares in the last quarter. Sunbelt Securities Inc. lifted its position in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new position in shares of GSK during the fourth quarter worth $32,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GSK has been the topic of a number of recent research reports. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 0.9 %

Shares of NYSE:GSK opened at $39.24 on Friday. The stock has a market capitalization of $81.32 billion, a price-to-earnings ratio of 24.68, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The company’s fifty day moving average is $35.93 and its two-hundred day moving average is $37.13. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.01%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio is 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.